{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:45:03Z","timestamp":1792622703486,"version":"4.5.0"},"reference-count":37,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020707","name":"Janssen Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020707","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,7,31]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate the efficacy and safety of ustekinumab (UST) in a multicentre, randomised, double-blind, placebo-controlled trial in adult Japanese patients with active polymyositis (PM) and dermatomyositis (DM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Fifty-one Japanese adults diagnosed with active PM\/DM who did not respond adequately to one or more standard-of-care treatments were randomised 1:1 to receive UST (n=25) or placebo (n=26). Participants received body weight-range based intravenous administration of UST (6\u2009mg\/kg) or placebo at week 0 followed by 90\u2009mg subcutaneous (SC) administration of UST or placebo every 8 weeks from week 8 to week 24. At week 24, placebo group crossed over to receive body weight-range based intravenous administration of UST, and thereafter, all participants received\/were to receive SC administration of UST 90\u2009mg every 8 weeks (week 32 through to week 72). The primary efficacy endpoint was the proportion of participants who achieved minimal improvement (\u226520) in the International Myositis Assessment and Clinical Studies Total Improvement Score (IMACS TIS) at week 24.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>No statistically significant difference was seen in the proportion of participants who achieved minimal improvement (\u226520) in IMACS TIS at week 24 between the treatment groups (UST 64.0% vs placebo 61.5%, p=0.94) based on the primary estimand of the primary endpoint analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>UST was safe and well tolerated but did not meet the primary efficacy endpoint in adult Japanese participants with active PM\/DM based on the primary analysis at week 24 in the study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03981744\">NCT03981744<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003268","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T12:34:55Z","timestamp":1693485295000},"page":"e003268","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments"],"prefix":"10.1136","volume":"9","clinical-trial-number":[{"clinical-trial-number":"nct03981744","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-9987","authenticated-orcid":false,"given":"Kimito","family":"Kawahata","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Allergology, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5361-5824","authenticated-orcid":false,"given":"Tomonori","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2593-1771","authenticated-orcid":false,"given":"Takahisa","family":"Gono","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9161-4708","authenticated-orcid":false,"given":"Yumi","family":"Tsuchiya","sequence":"additional","affiliation":[{"name":"Research and Development, Janssen Pharmaceutical KK, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Research and Development, Janssen Pharmaceutical KK, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yoshizawa","sequence":"additional","affiliation":[{"name":"Research and Development, Janssen Pharmaceutical KK, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Statistics and Decision Sciences, Janssen Pharmaceutical KK, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maori","family":"Ayabe","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Pharmacometrics, Janssen Pharmaceutical KK, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Research and Development, Janssen Pharmaceutical KK, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"2025090313582154000_9.3.e003268.1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/14397595.2018.1467257","article-title":"Current diagnosis and treatment of polymyositis and dermatomyositis","volume":"28","author":"Sasaki","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025090313582154000_9.3.e003268.2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100018","article-title":"Polymyositis and dermatomyositis \u2013 challenges in diagnosis and management","volume":"2","author":"Yang","year":"2019","journal-title":"J Transl Autoimmun"},{"key":"2025090313582154000_9.3.e003268.3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/14397595.2013.844308","article-title":"Prevalence and incidence of polymyositis and dermatomyositis in Japan","volume":"24","author":"Ohta","year":"2014","journal-title":"Modern Rheumatology"},{"key":"2025090313582154000_9.3.e003268.4","unstructured":"Intractable Diseases Information Center Japan . Number of holders of specific medical expenses (designated intractable disease) recipient certificate \u2013 intractable disease information center. 2023. Available: https:\/\/www.nanbyou.or.jp\/entry\/5354"},{"key":"2025090313582154000_9.3.e003268.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30254-0"},{"key":"2025090313582154000_9.3.e003268.6","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000855"},{"key":"2025090313582154000_9.3.e003268.7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40674-018-0106-2","article-title":"Current treatment for myositis","volume":"4","author":"Barsotti","year":"2018","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2025090313582154000_9.3.e003268.8","doi-asserted-by":"crossref","unstructured":"Moghadam-Kia S , Oddis CV . Current and new targets for treating myositis. Curr Opin Pharmacol 2022;65. doi:10.1016\/j.coph.2022.102257","DOI":"10.1016\/j.coph.2022.102257"},{"key":"2025090313582154000_9.3.e003268.9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"2025090313582154000_9.3.e003268.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2010.03.011"},{"key":"2025090313582154000_9.3.e003268.11","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-020-00943-2","article-title":"Promising and upcoming treatments in myositis","volume":"22","author":"Smith","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2025090313582154000_9.3.e003268.12","doi-asserted-by":"crossref","unstructured":"Glaubitz S , Zeng R , Schmidt J . New insights into the treatment of myositis. Ther Adv Musculoskelet Dis 2020;12. doi:10.1177\/1759720X19886494","DOI":"10.1177\/1759720X19886494"},{"key":"2025090313582154000_9.3.e003268.13","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMe2209117","article-title":"Intravenous immune globulin therapy in dermatomyositis","volume":"387","author":"Amato","year":"2022","journal-title":"N Engl J Med"},{"key":"2025090313582154000_9.3.e003268.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of Rituximab treatment in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"key":"2025090313582154000_9.3.e003268.15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/03009742.2010.517215","article-title":"Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis","volume":"40","author":"Shen","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"2025090313582154000_9.3.e003268.16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-23539-4","article-title":"Interleukin-23 as a therapeutic target for inflammatory myopathy","volume":"8","author":"Umezawa","year":"2018","journal-title":"Sci Rep"},{"key":"2025090313582154000_9.3.e003268.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.04.016"},{"key":"2025090313582154000_9.3.e003268.18","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.1700053"},{"key":"2025090313582154000_9.3.e003268.19","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.4103\/0366-6999.213419","article-title":"Upregulation of interleukin 21 and interleukin 21 receptor in patients with dermatomyositis and polymyositis","volume":"130","author":"Liu","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"2025090313582154000_9.3.e003268.20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/cei.12475","article-title":"Quantitative T cell subsets profile in peripheral blood from patients with idiopathic inflammatory myopathies: tilting the balance towards proinflammatory and pro-apoptotic Subsets","volume":"179","author":"Espinosa-Ortega","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2025090313582154000_9.3.e003268.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.33350"},{"key":"2025090313582154000_9.3.e003268.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.26"},{"key":"2025090313582154000_9.3.e003268.23","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X13501021"},{"key":"2025090313582154000_9.3.e003268.24","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.640813","article-title":"How to optimize treatment with ustekinumab in inflammatory bowel disease: lessons learned from clinical trials and real-world data","volume":"8","author":"Guti\u00e9rrez","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025090313582154000_9.3.e003268.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203572"},{"key":"2025090313582154000_9.3.e003268.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"2025090313582154000_9.3.e003268.27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/RHU.0000000000000430","article-title":"A rare case of Amyopathic juvenile dermatomyositis associated with psoriasis successfully treated with ustekinumab","volume":"23","author":"Montoya","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2025090313582154000_9.3.e003268.28","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/rheumatology\/kez020","article-title":"Successful treatment of refractory mechanic\u2019s hands with ustekinumab in a patient with the antisynthetase syndrome","volume":"58","author":"Pinal-Fernandez","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313582154000_9.3.e003268.29","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-8-18","article-title":"Statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"2025090313582154000_9.3.e003268.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"2025090313582154000_9.3.e003268.31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","article-title":"American college of rheumatology\/European league against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international myositis assessment and clinical studies group\/paediatric rheumatology international trials organisation collaborative initiative","volume":"69","author":"Aggarwal","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"2025090313582154000_9.3.e003268.32","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/acr2.11493","article-title":"Randomized trial of Tocilizumab in the treatment of refractory adult polymyositis and dermatomyositis","volume":"4","author":"Oddis","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"2025090313582154000_9.3.e003268.33","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-022-06242-8","article-title":"Correction to: disease burden and treatment sequence of polymyositis and dermatomyositis patients in Japan: a real-world evidence study","volume":"41","author":"Miyazaki","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2025090313582154000_9.3.e003268.34","first-page":"1424","article-title":"Patient-reported dermatomyositis and polymyositis flare symptoms are associated with disability, productivity loss, and health care resource use","volume":"26","author":"Christopher-Stine","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"key":"2025090313582154000_9.3.e003268.35","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190008"},{"key":"2025090313582154000_9.3.e003268.36","doi-asserted-by":"crossref","unstructured":"Aggarwal R , Charles-Schoeman C , Schessl J , et al . \u201cProspective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of Octagam 10% in patients with dermatomyositis (\"Proderm study\")\u201d. Medicine (Baltimore) 2021;100. doi:10.1097\/MD.0000000000023677","DOI":"10.1097\/MD.0000000000023677"},{"key":"2025090313582154000_9.3.e003268.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.4518"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:58:33Z","timestamp":1756933113000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,8,31]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/rmdopen-2023-003268"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003268","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}